Cooley's Anemia Foundation (CAF)

Efficacy and safety of betibeglogene autotemcel (beti-cel) gene therapy in 63 patients with transfusion-dependent β-thalassemia (TDT): 7-year post-infusion follow-up of phase 1/2 and phase 3 studies.

Authors: Kwiatkowski JL.